ASH2023注目テーマ①「Late-Breaking Abstracts Session #1」

移植適応の初発MM に対するVRd療法への
ダラツムマブの追加は、PFS延長と深い奏効を導く Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial (#LBA-1)

Pieter Sonneveld（Erasmus MC Cancer Institute, Rotterdam, Netherlands）